<DOC>
	<DOCNO>NCT00834353</DOCNO>
	<brief_summary>N-acetyltransferase2 ( NAT2 ) Cytochrome P4502E1 ( CYP2E1 ) two drug metabolize enzyme . Antituberculosis drug isoniazid acetylate NAT2 form ultimately nontoxic compound metabolize CYP2E1 toxic metabolite . Slow acetylator genotype NAT2 wild type genotype CYP2E1 gene attribute great toxicity ATT drug . Therefore study design analyze genetic polymorphism NAT2 CYP2E1 gene tuberculosis patient develop drug induce hepatitis upon administration antituberculosis drug.Polymorphism study NAT2 CYP2E1 gene may help predict high risk group ATT induce hepatitis .</brief_summary>
	<brief_title>Prospective Study N-acetyltransferase2 ( NAT2 ) Cytochrome P4502E1 ( CYP2E1 ) Gene Susceptible Risk Factors Antituberculosis ( ATT ) Induced Hepatitis</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Antitubercular Agents</mesh_term>
	<criteria>Patients pulmonary tuberculosis Patients receive conventional antituberculosis drug Patients directly present antituberculosis drug induce hepatitis Habitual alcohol drinker Patients evidence viral hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>